

# Puma Biotechnology

## Earnings Call

### Commercial Update



**August 1, 2024**

**nerlynx<sup>®</sup>**  
(neratinib) tablets




## Forward-Looking Safe-Harbor Statement

*This presentation contains forward-looking statements, including statements regarding commercialization of NERLYNX® and the potential indications and development of our drug candidates. All forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on our current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors, which include, but are not limited to, any adverse impact on our business or the global economy and financial markets, generally, from the global COVID-19 pandemic, and the risk factors disclosed in our periodic and current reports filed with the Securities and Exchange Commission from time to time, including our Annual Report on Form 10-K for the year ended December 31, 2023 and subsequent filings. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We assume no obligation to update these forward-looking statements except as required by law.*




# Puma's Pharmacy and Distributor Network



# \$44.4 Million Net NERLYNX Revenue in Q2'24


*~14% decline in Q2'24 compared to Q2'23*



Inventory Change (\$)

Q2'23	Q2'24
-\$1.5 mil	-\$2.3 mil

*~10% increase in Q2'24 compared to Q1'24*




Inventory Change (\$)

Q1'24	Q2'24
-\$2.0 mil	-\$2.3 mil

# 2,515 Ex-Factory Bottles Were Sold in Q2'24


*~17% decline in Q2'24 compared to Q2'23*



**Inventory Change Bottles**

Q2'2023	Q2'2024
-90	-132

*~4% increase in Q2'24 compared to Q1'24*




**Inventory Change Bottles**

Q1'2024	Q2'2024
-120	-132







# ~66% of Patients in Q2'24 Started at a Reduced Dose\*

% of Patients Starting at Reduced Dose



\*Reduced dose defined as fewer than 6 pills per day

# Rest of World Partnerships – Timelines

Region	Partner	Regulatory Approvals	Commercial Launches
Australia / SE Asia	 Specialised Therapeutics	<ul style="list-style-type: none"> <li>• 2019 – Ext. Adj. in Australia, Singapore</li> <li>• 2020 – Ext. Adj. in Brunei, Malaysia, New Zealand</li> <li>• 2022 – Ext. Adj. in the Philippines; mBC in Singapore</li> <li>• 2023 – mBC in Malaysia</li> </ul>	<ul style="list-style-type: none"> <li>• 2020 – Singapore</li> <li>• 2021 – Malaysia, Brunei, New Zealand</li> </ul>
Israel	 MEDISON Driving Innovative Healthcare	<ul style="list-style-type: none"> <li>• 2020 – Approved in Ext. Adj. and mBC</li> </ul>	<ul style="list-style-type: none"> <li>• 2020 – Launched</li> </ul>
Canada	 Knight	<ul style="list-style-type: none"> <li>• 2019 – Ext. Adj. approved</li> <li>• 2021 – mBC approved</li> </ul>	<ul style="list-style-type: none"> <li>• 2020 – Launched</li> </ul>
Latin America	 PINT PHARMA	<ul style="list-style-type: none"> <li>• 2019 – Ext Adj in Argentina</li> <li>• 2020 – Ext. Adj in Chile, Ecuador; mBC in Argentina</li> <li>• 2021 – Ext Adj. and mBC in Peru; mBC in Chile; Ext. Adj. in Brazil</li> <li>• 2022 – Ext. Adj. in Mexico; mBC in Ecuador</li> <li>• 2023 – mBC in Colombia and Mexico</li> <li>• <b>Q2 2024 – mBC in Brazil</b></li> </ul>	<ul style="list-style-type: none"> <li>• 2020 – Argentina</li> <li>• 2021 – Chile and Peru</li> <li>• 2022 – Brazil</li> <li>• Q1 2023 – Mexico and Colombia</li> </ul>
Europe Greater China Middle East North and West Africa South Africa Turkey	 Pierre Fabre	<ul style="list-style-type: none"> <li>• 2019 – Ext. Adj. EMA and Hong Kong</li> <li>• 2020 – Ext. Adj. in China, Taiwan</li> <li>• 2021 – mBC in Taiwan</li> <li>• 2023 – Ext. Adj. in Morocco, South Africa, and UAE</li> <li>• Q1 2024 – Ext. Adj. in Syria</li> <li>• <b>Q2 2024 – Ext. Adj. in Saudi Arabia</b></li> </ul>	<ul style="list-style-type: none"> <li>• 2019 – Germany, UK, Austria</li> <li>• 2020 – Sweden, Finland, Scotland, Switzerland, Denmark, and Hong Kong</li> <li>• 2021 – China (added to 2021 NRDL), Taiwan, Greece, Czech Republic, and Luxembourg</li> <li>• 2022 – Ireland and Spain</li> <li>• 2023 – Slovakia</li> <li>• Q1 2024 – Morocco</li> <li>• <b>Q3 2024 – South Africa</b></li> </ul>
South Korea	 BIXINK THERAPEUTICS	<ul style="list-style-type: none"> <li>• 2021 – Ext. Adj. in S. Korea</li> </ul>	<ul style="list-style-type: none"> <li>• 2022 – Launched</li> </ul>

# Puma Biotechnology

## Earnings Call

### Commercial Update



**August 1, 2024**

**nerlynx<sup>®</sup>**  
(neratinib) tablets

